
Clinical
Latest News
Advertisement
Latest Videos

CME Content
Advertisement
More News

























Tumor response rate and progression-free survival were the benchmarks that helped pembrolizumab (Keytruda) gain accelerated approval as first-line treatment for metastatic nonsquamous non-small cell lung cancer (NSCLC), in combination with chemotherapy.
Advertisement
Advertisement
Trending on AJMC
1
Bills to Address Expiring ACA Subsidies Fail to Pass Senate
2
Advancing Early Detection and Equitable Access in Alzheimer Disease Care
3
ICYMI: Highlights From SPD 2025
4
In CLL, New Therapies Offer Potential for Personalized Approaches
5
















































